Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443532 | 0.88 | DGAT1 (0.52) | NPC1LMNARAB9ADGAT1KDM4E | |
| SCHEMBL408901 | 0.88 | NPC1 (0.60) | NPC1LMNARAB9ADGAT1KDM4E | |
| SCHEMBL408172 | 0.84 | NPSR1 (0.60) | NPC1RAB9ADGAT1NPSR1MAPK1 | |
| SCHEMBL19795577 | 0.82 | JUN (0.50) | NPC1RAB9ADGAT1KDM4ENPSR1 | |
| SCHEMBL4300650 | 0.82 | NPSR1 (0.59) | NPC1LMNARAB9ADGAT1KDM4E | |
| SCHEMBL24303811 | 0.81 | CA12 (0.56) | NPC1LMNARAB9ADGAT1KDM4E | |
| SCHEMBL408365 | 0.81 | DGAT1 (0.59) | NPC1LMNARAB9ADGAT1KDM4E | |
| SCHEMBL16691194 | 0.81 | DGAT1 (0.55) | NPC1LMNADGAT1KDM4ENPSR1 | |
| SCHEMBL4298281 | 0.81 | DGAT1 (0.66) | NPC1RAB9ADGAT1NPSR1MAPK1 | |
| SCHEMBL22324675 | 0.81 | DGAT1 (0.55) | NPC1LMNARAB9ADGAT1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | NPC1 142/4885LMNA 4016/4885RAB9A 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.